A retrospective cohort study to investigate the time to treatment discontinuation and database persistence for patients with first-line metastatic pancreatic cancer treated with nab-paclitaxel and gemcitabine and FOLFIRINOX
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 27 Jan 2016 New trial record
- 22 Jan 2016 Results from this trial were presented at the 2016 ASCO Gastrointestinal Cancers Symposium (ASCO GI), according to a Celgene Corporation media release.
- 22 Jan 2016 Results published in a Celgene Corporation media release.